Epigral targets growth by FY31 with capacity expansionsIllustrative image – not actual.

Epigral is targeting a revenue of Rs 5,000 crore by the 2030-31 financial year, propelled by upcoming production scale-up at its manufacturing complex in Dahej, Gujarat.

Epigral’s Chairman and Managing Director, Maulik Patel, announced that the company is doubling its CPVC Resin capacity from 75,000 to 1,50,000 TPA and its ECH capacity from 50,000 to 1,00,000 TPA. Both expansion projects, backed by a Rs 650-crore capital expenditure funded entirely through internal accruals, are set to be commissioned within months and will contribute meaningfully to the topline starting next year.

By leveraging a sustainable, 100 percent renewable glycerine-based process for ECH and doubling its CPVC output, Epigral is positioned to become the world's largest manufacturer in the CPVC category while advancing import substitution.

 

← All latest storiesBack to top →